

Special Issue

Drug Screening or Toxicology Research Based on 3D-Cultured Cell Models

Message from the Guest Editor

In this Special Issue, we intend to widen our knowledge about the potential of grafting 3D cultured cell models onto the areas of drug screening and toxicology. From a fundamental hurdle in a two-dimensional (2D) cell culture approach, which is a lack of representation of the microenvironment of in vivo tissue, to date, the demand for the development of three-dimensional (3D) cell culture platforms in both/either drug screening and/or toxicology is gradually magnified. In this regard, it is confidently expected that the similarity of 3D cell cultures to in vivo tissue provides the reliability in drug screening with in-depth understanding of the toxic nature of substances. Herein, we hope that this Special Issue opens up a new promising way to underpin the capability of 3D cultured cell platforms (e.g., spheroids, hanging drop, bioreactors, cell culture scaffolds, and any of the 3D co-cultured fashions) toward either drug screening or toxicology research with a multidisciplinary approach.

- three-dimensional cell cultures
- spheroids
- scaffolds
- bioreactors
- drug screening
- toxicology

Guest Editor

Dr. Dukjin Kang

Biometrology Group, Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea

Deadline for manuscript submissions

closed (28 February 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/84286

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).